Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125761011 | 12576101 | 1 | I | 201508 | 20160711 | 20160720 | 20160720 | EXP | US-SA-2016SA128925 | AVENTIS | 87.00 | YR | E | F | Y | 69.80000 | KG | 20160720 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125761011 | 12576101 | 1 | PS | LANTUS | INSULIN GLARGINE | 1 | Unknown | U | NK | 21081 | |||||||||
125761011 | 12576101 | 2 | SS | LANTUS | INSULIN GLARGINE | 1 | Unknown | U | UNK | 21081 | 1X | ||||||||
125761011 | 12576101 | 3 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | AD6457F | 0 | 15 | MG | TABLET | QD | ||||||
125761011 | 12576101 | 4 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | AD6457F | 0 | 15 | MG | TABLET | QD | ||||||
125761011 | 12576101 | 5 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | UNK | 0 | 15 | MG | TABLET | QD | ||||||
125761011 | 12576101 | 6 | SS | JAKAFI | RUXOLITINIB | 1 | Oral | UNK | 0 | 15 | MG | TABLET | QD | ||||||
125761011 | 12576101 | 7 | SS | NOVOLOG | INSULIN ASPART | 1 | Unknown | U | UNK | 0 | |||||||||
125761011 | 12576101 | 8 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 9 | C | ATENOLOL. | ATENOLOL | 1 | 0 | ||||||||||||
125761011 | 12576101 | 10 | C | BALSALAZIDE | BALSALAZIDE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 11 | C | CALCIUM | CALCIUM | 1 | 0 | ||||||||||||
125761011 | 12576101 | 12 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
125761011 | 12576101 | 13 | C | FISH OIL | FISH OIL | 1 | 0 | ||||||||||||
125761011 | 12576101 | 14 | C | LASIX | FUROSEMIDE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 15 | C | WARFARIN | WARFARIN | 1 | 0 | ||||||||||||
125761011 | 12576101 | 16 | C | CEFUROXIME. | CEFUROXIME | 1 | 0 | ||||||||||||
125761011 | 12576101 | 17 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 18 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 19 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | ||||||||||||
125761011 | 12576101 | 20 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 21 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
125761011 | 12576101 | 22 | C | ASACOL | MESALAMINE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 23 | C | COUMADIN | WARFARIN SODIUM | 1 | 0 | ||||||||||||
125761011 | 12576101 | 24 | C | GAS-X | DIMETHICONE | 1 | 0 | ||||||||||||
125761011 | 12576101 | 25 | C | LISINOPRIL. | LISINOPRIL | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125761011 | 12576101 | 3 | Myelofibrosis |
125761011 | 12576101 | 4 | Myelofibrosis |
125761011 | 12576101 | 5 | Myelofibrosis |
125761011 | 12576101 | 6 | Myelofibrosis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125761011 | 12576101 | OT |
125761011 | 12576101 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125761011 | 12576101 | Anaemia | |
125761011 | 12576101 | Contusion | |
125761011 | 12576101 | Pneumonia | |
125761011 | 12576101 | Pulmonary thrombosis | |
125761011 | 12576101 | Shock hypoglycaemic | |
125761011 | 12576101 | Splenomegaly | |
125761011 | 12576101 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125761011 | 12576101 | 3 | 20120723 | 0 | ||
125761011 | 12576101 | 4 | 20120723 | 0 |